Wells Fargo & Company MN Sells 119,558 Shares of Autolus Therapeutics plc (NASDAQ:AUTL)

Wells Fargo & Company MN reduced its stake in Autolus Therapeutics plc (NASDAQ:AUTL) by 31.0% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 266,315 shares of the company’s stock after selling 119,558 shares during the period. Wells Fargo & Company MN owned 0.10% of Autolus Therapeutics worth $626,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Candriam S.C.A. acquired a new position in Autolus Therapeutics in the fourth quarter valued at about $7,500,000. Wellington Management Group LLP raised its position in shares of Autolus Therapeutics by 4.6% in the 4th quarter. Wellington Management Group LLP now owns 25,345,680 shares of the company’s stock valued at $59,562,000 after acquiring an additional 1,125,454 shares during the period. JPMorgan Chase & Co. raised its position in shares of Autolus Therapeutics by 145.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,284,708 shares of the company’s stock valued at $4,663,000 after acquiring an additional 761,008 shares during the period. BIT Capital GmbH boosted its stake in Autolus Therapeutics by 147.0% during the 4th quarter. BIT Capital GmbH now owns 636,979 shares of the company’s stock worth $1,497,000 after acquiring an additional 379,050 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. acquired a new position in Autolus Therapeutics during the fourth quarter valued at approximately $611,000. 72.83% of the stock is owned by institutional investors and hedge funds.

Autolus Therapeutics Price Performance

Shares of AUTL opened at $1.35 on Friday. The firm has a market capitalization of $359.23 million, a PE ratio of -1.12 and a beta of 2.06. The company’s 50-day moving average is $1.58 and its 200-day moving average is $2.37. Autolus Therapeutics plc has a fifty-two week low of $1.11 and a fifty-two week high of $5.00.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings results on Thursday, March 20th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.12. The firm had revenue of $0.03 million during the quarter, compared to the consensus estimate of $2.98 million. Analysts predict that Autolus Therapeutics plc will post -0.94 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have issued reports on AUTL. Wells Fargo & Company lowered their price target on Autolus Therapeutics from $8.00 to $6.00 and set an “overweight” rating for the company in a report on Friday, March 21st. Needham & Company LLC reiterated a “buy” rating and issued a $10.00 price target on shares of Autolus Therapeutics in a research note on Thursday, April 10th. Finally, Truist Financial dropped their price objective on Autolus Therapeutics from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, April 1st. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Autolus Therapeutics currently has an average rating of “Buy” and an average price target of $9.32.

Autolus Therapeutics Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.